Quest PharmaTech Brief: Says Quest Has a 42.5% Ownership Interest in OncoQuest; Adds Dividend Income Will Be Used by Quest for General Corporate Purposes

MT NewswiresJan 30 17:07 ET

Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis

MT NewswiresJan 24 07:07 ET

Quest PharmaTech Provides Corporate Update

Stockhouse Sep 13, 2023 16:15 ET

Quest PharmaTech Announces Results From AGM

Stockhouse Jul 14, 2023 16:30 ET

Quest PharmaTech Provides Product Development Update

Stockhouse Jul 10, 2023 16:30 ET